Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Inhaled LAMAs are recommended for COPD patients in all GOLD groups (A,B,C&D)¹. GLY 50µg is effective and well tolerated in moderate-to-severe COPD patients, similar to TIO 18µg, and with faster onset and better bronchodilation in the first 4h after the first dose.The effect of GLY and TIO in patients categorized by GOLD group was analyzed post hoc using data from 4 randomized controlled clinical trials pooled and adjusted using mix-model. GOLD classification was done based on baseline St George's Respiratory Questionnaire (SGRQ) score (cut point=25) and lung function (FEV₁; </> 50% predicted normal) without baseline exacerbation risk. Efficacy of GLY and TIO was analyzed by mean change from baseline at 12 wks for trough FEV₁ (tFEV₁), SGRQ score, and TDI score.Of 2599 patients (GLY=1628, TIO=971), 7.6%, 52.6%, 2.8% and 37.0% were classed in GOLD groups A, B, C and D respectively. GLY showed significant improvement in tFEV₁ in patients in all groups after 12 treatment wks compared with baseline; TIO showed significant improvement only in B&D groups. In group A, GLY was significantly better than TIO [least square means difference for tFEV₁ GLY vs TIO: 75 ml (CI: 25, 125; p=0.0036)]. GLY significantly improved dyspnea in patients in all GOLD groups, similar to TIO. GLY and TIO showed similar and significant improvement in SGRQ only in GOLD groups B&D.In conclusion, GLY and TIO significantly improved dyspnea (in all GOLD groups) and health status (GOLD Groups B&D). GLY provided significant improvement in tFEV₁ in patients in all GOLD groups, while TIO showed statistically significant improvement in tFEV₁ only in patients in group B&D.1. GOLD 2015.


Rating:

Share or cite this content

Citations should be made in the following way:
Anthony D. D'Urzo (Toronto, Canada), Anthony D’Urzo, Giovanni Bader, Pablo Altman, Pankaj Goyal. Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups. Eur Respir J 2015; 46: Suppl. 59, 1010

Member's Comments

No comment yet.

Related content which might interest you: Glycopyrronium significantly improves lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Onset of action of aclidinium (ACL), glycopyrronium (GLY) and tiotropium (TIO): A comparison in COPD patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Comparative evaluation on the synergism of roflumilast (RFL) and glycopyrronium (Gly) vs ciclesonide (CLS) and Gly on lung volumes and exercise tolerance in severe COPD Source: International Congress 2015 – Clinical exercise physiology in health and disease Year: 2015 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015